Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?

M Martínez-Bonet¹, MI Clemente¹, ², MJ Serramía³, S Moreno³, E Muñoz⁴, MA Muñoz-Fernández¹※

¹Servicio de Inmunología, Laboratorio Inmunobiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; Spanish HIV GCM Biobank and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
²Plataforma de Cultivos Celulares, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain
³Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal and IRYCIS, Madrid, Spain
⁴Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigaciones Biomédicas de Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain

Abstract

The limitations to establishing a viral reservoir facilitated by early cART in children could play a critical role in achieving natural control of viral replication upon discontinuation of cART, which could be defined as ‘functional cure’. Viral reservoirs could provide a persistent source of recrudescent viremia after withdrawal of cART, despite temporary remission of HIV-1 infection, as observed in the ‘Mississippi baby’. Intensification of cART has been proposed as a strategy to control residual replication and to diminish the reservoirs. The effects of cART intensification with maraviroc persisted after discontinuation of the drug in HIV-1-infected adults. However, in HIV-1-infected children, the emergence of CCR5 using variants occurs very early, and the use of CCR5 antagonists in these children as intensification therapy may not be the best alternative. New treatments to eradicate HIV-1 are focused on the activation of viral production from latently infected cells to purge and clear HIV-1 reservoirs. This strategy involves the use of a wide range of small molecules called latency-reversing agents (LRAs). Histone deacetylase inhibitors (HDACi) such as givinostat, belinostat and panobinostat, and class I-selective HDACis that include oxamflatin, NCH-51 and romidepsin, are the most advanced in clinical testing for HIV-1 LRAs. Panobinostat and romidepsin show an efficient reactivation profile in J89GFP cells, a lymphocyte HIV-1 latently infected cell line considered a relevant model to study post-integration HIV-1 latency and reactivation. Clinical trials with panobinostat and romidepsin have been performed in children with other pathologies and it could be reasonable to design a clinical trial using these drugs in combination with cART in HIV-1-infected children.

Key words: vertically acquired HIV-1 infection, HIV-reactivation, HIV-latency, panobinostat, romidepsin

Introduction

Combination antiretroviral therapy (cART) has raised the life expectancy, reduced the incidence of opportunistic infections and improved the quality of life of HIV-1-infected individuals. AIDS-related mortality in children has decreased significantly with the wide availability of cART. During recent years, multiple studies have suggested the benefit of early administration of cART in every HIV-1-infected infant [1–4]. Therefore, international guidelines are now recommending initiation of cART in all HIV-1-infected infants aged less than one year regardless of clinical and immunological conditions (http://whqlibdoc.who.int/publications/2010/9789241599801.eng.pdf, and http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf). HIV-1 infection is still a chronic infection with a great number of associated complications and cART needs to be administrated life-long [5]. Therefore, searching for an HIV-1 cure remains a priority. Two different forms of cure have been defined: (i) a ‘sterilising cure’, in which all replication-competent virus and infected cells are eliminated (such as in the ‘Berlin Patient’ [6]), and (ii) a ‘functional cure’, represented by ‘elite controllers’ who permanently control HIV-1 replication without cART [7] (such as in the ‘Mississippi baby case’). Both the Berlin patient and the Mississippi baby are exceptional, and both cases are completely different. HIV-1 infection has been eradicated in the Berlin patient, while the Mississippi baby maintained a low level of inactive latent virus, only detectable using sensitive droplet digital PCR [8]. Eradication in the Berlin patient was achieved after a complex medical process, while the Mississippi baby was the first case of a potential HIV-1 cure achieved using a only pharmacological cART. The reason for the success of this approach, which is known to be ineffective in adults, could rely on the particularities of the immune system that HIV-1 encounters in a fetus or a newborn. The main obstacle in achieving functional cure is the persistence of a viral reservoir, a pool of the HIV-1 genome integrated into long-living T cells, and probably in other haematopoietic cells such as macrophages [9].

Although cART achieves undetectable plasma viral RNA and the normalisation of CD4 T cell levels in almost every patient, several studies have shown that HIV-1 remains incurable owing to the persistence of latently infected cells [10–12]. The majority of these cells are resting memory and naïve CD4 T cells, and cells belonging to the monocyte/macrophage lineage that contain integrated proviruses within their genome. These cells are the main force behind HIV-1 persistence under cART, which only impacts on actively replicating viruses and is therefore unable to eradicate the infection. For this reason, the most recent approaches to HIV cure are focused on the definition of new drug families that do not target the replication of HIV but rather the transcription of proviruses in CD4 T cells. In combination with cART, these drugs would make HIV-1 visible and harmless to the immune system. This may be achieved by implementing both pharmacological and immunological strategies to reactivate HIV-1 from latently infected cells. Nevertheless, reactivation may not be sufficient to eradicate the virus. Reinforcing HIV-1-specific immune responses and blocking potential new events of viral replication will probably help in reaching the final goal of eradication, or the alternative objective of a ‘functional cure’ for HIV-1 infection.
Persistence of the viral reservoir

In HIV-1-infected adults, the pool of latently infected resting CD4+ T cells has been the most intensely analysed HIV-1 reservoir, and is widely recognised as one of the major barriers to achieving eradication or ‘functional cure’ of HIV-1 infection [13–16]. First, the absence of consensus on stability of the viral reservoir caused a storm of controversy concerning the possibility that residual HIV-1 replication in subsets of CD4+ T cells in the lymphoid tissue may contribute to replenishment of the HIV-1 reservoir [17–21]. Secondly, HIV-1 infects CD4+ T cells and requires some level of immune activation to replicate. HIV-1 infects mostly memory cells, in particular cells from gut-associated lymphoid tissue (GALT), which concentrates most of the activated CCR5-expressing memory CD4+ T cells. Various groups have drawn attention to GALT as a major HIV-1 reservoir in individuals receiving cART, since CD4+ T cell recovery is poorer in GALT, and viral replication remains higher with respect to peripheral blood. This persistent viral replication in GALT probably contributes to maintenance of the reservoir despite peripheral viral suppression [17,22–24]. GALT depletion is a major pathogenic event in HIV-1 infection and is associated with the establishment of a long-lived viral reservoir and disease progression in HIV-1-infected adults [25]. In contrast, in the immunological setting of a fetus, memory cells are virtually absent from the CD4 T cell compartment [26] and GALT is anatomically immature, since it requires commensal bacteria for full development [27]. In the absence of an optimal setting for replication, HIV-1 may be unable to establish a long-lived latent reservoir and therefore, under this particular situation, very early treatment could have an additional beneficial effect that cannot be observed in chronically HIV-1-infected adults.

HIV-infected children who initiate cART soon after birth do not display HIV-1-specific antibodies or cellular responses, thus indicating early control of viral replication [28,29]. Nevertheless, HIV-1 infection quickly establishes a viral reservoir, mainly in resting memory CD4+ T cells. Although the memory T cell population in peripheral blood is small in newborns [30], although ready to develop later in childhood [31], recent findings have shown the presence of HIV-1-susceptible memory CD4+ T cells in the gut of newborns with predominantly T helper- (Th) 1 and Th17 phenotype, highlighting that extensive adaptive immunity is present before birth and the gut mucosa is the preferential site for memory CD4+ T cells [32]. The limitations to establishing a long-lived viral reservoir facilitated by early cART in children could play a critical role in achieving natural control of viral replication upon discontinuation of cART, which could be defined as ‘functional cure’ [31,33–36]. On the other hand, viral reservoirs could provide a persistent source of recrudescent viremia despite temporary remission of HIV-1 infection after withdrawal of cART [37], as observed in the Mississippi baby [8].

Intensification of effective cART

Intensification of effective cART has been proposed as a strategy to control residual replication and to diminish the HIV-1 reservoirs [38]. Despite some studies having failed to show any effect of ART intensification on the residual HIV-1 viremia in patients with a history of chronic infection receiving cART [39], a study of 48 weeks’ intensification with maraviroc has been associated with a trend towards a decrease in the size of the latent HIV-1 reservoir in memory T cells in chronically HIV-1–infected patients on cART [40].

CCR5 receptor antagonists in the pipeline are of particular interest because of their mechanisms of action, which could provide a beneficial anti-inflammatory effect beyond their antiviral activity. This immunomodulation represents an added benefit because it could improve the treatment of HIV-associated chronic immunomodulation [25]. This condition increases the risk for serious non-AIDS-related illnesses, such as heart disease, metabolic complications, kidney problems and others. Interestingly, potentially important anti-inflammatory effects have been highlighted for cenicriviroc, which inhibits the CCR2 receptor regulating rapid monocyte mobilisation [41,42]. A body of evidence from Phase II/III clinical trials of investigational CCR5 antagonists (maraviroc and vicriviroc) in treatment-experienced HIV-1 adults indicates a 30 cells/μL [95% confidence interval (CI) 19–42] greater increase in CD4+ T cell count in individuals using CCR5 antagonists (maraviroc or vicriviroc) than in groups not using CCR5 antagonists, despite baseline plasma HIV-1 RNA and virological suppression. Robust immunological effects were also observed in antiretroviral-naive subjects included in the MERIT clinical trial, when the group randomised to receive maraviroc showed greater increases in CD4+ T cell count than did those receiving efavirenz [43]. The efficacy of cART intensification with the addition of maraviroc has also been studied in individuals with incomplete CD4+ T cell recovery, due to the potential role of maraviroc on immunological recovery [43]. This intensification is clinically relevant mainly for subjects with low CD4+ T cell count, to avoid overall HIV-1–related mortality and morbidity [44–46].

While some researchers reported that 24 weeks of maraviroc intensification was not associated with a CD4+ T cell gain of at least 20 cells/μL [47], others researchers observed immunological benefits [48]. Although the mechanism of this effect is still unknown, the blockage of the CCR5 receptor with maraviroc was associated with an increase in circulating levels of CCR5 ligands [48–50]. Because these ligands may also signal through alternative chemokine receptors, such as CCR1, CCR3 and CCR4 [51–53], the maraviroc-mediated activation of immune cells through alternative chemokine receptors requires further investigation [48]. Interestingly, the results of two clinical trials showed the dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of cART. The effects of cART intensification with maraviroc or raltegravir persisted at least 24 weeks after discontinuation of the drug [54,55]. However, it is very important to note the emergence of CXCR4–using HIV-1 variants in a minority of HIV-1–infected patients following treatment with the CCR5 antagonist maraviroc, which probably developed from a pre-treatment CXCR4–using viral reservoir [56]. Because, in vertically HIV-1–infected children, the emergence of CXCR4–using variants occurs very early [57], the use of CCR5 antagonists in these children as intensification therapy may not be the best alternative.

Latency-reversing agents

The establishment of long-lived latent HIV-1 reservoirs involves multiple processes and is mainly due to transcriptional gene silencing in resting memory CD4+ T lymphocytes and other non-dividing cell types, including monocytes. New compounds targeting transcriptional repression have been recently proposed as pharmacological agents for purging latent HIV-1 from cellular reservoirs in individuals on cART. These pharmacological compounds should be coupled with very potent CART, which will prevent reactivated virus from infecting new host cells, while viral cytopathic effects and immune clearance will eliminate HIV-1–infected cells. Treatments for eradicating HIV-1 are focused on the activation of viral production from latently infected cells to purge and clear HIV-1 reservoirs. This strategy involves the use of a wide range of small molecules called latency-reversing agents (LRAs) [58]. These drugs include:
(i) histone deacetylase inhibitors (HDACis) [59]; (ii) disulfiram, postulated to involve nuclear factor κB cells (NF-κB) [60,61]; (iii) the bromodomain-containing protein 4 (BRD4) inhibitor JQ1, which elicits effects through positive transcription of the elongation factor (P-TEFb) [62]; and (iv) protein kinase C (PKC) activators such as ingenols [63], prostratin [64], 1,2-diacetylglycerol analogues [65] and bryostatin-1 [66-68].

The interest in these drugs has increased greatly and there are several clinical trials in progress investigating the safety and the effect of LRAs as disruptors of HIV latency. HDACis are the most advanced in clinical testing as HIV-1 anti-latency agents, due mainly to the synthesis in recent years of novel and more specific pan-HDACis such as givinostat, belinostat and panobinostat [69,70] and newly synthesised class I selective HDACis that include oxamflatin [71], NCH-51 [72] and romidepsin [73].

Recently published results from a clinical trial of the safety and the effect of panobinostat on HIV-1 expression in patients on suppressive cART postulated this compound as a promising reactivator of HIV-1 latency [70].

Both panobinostat and romidepsin show an efficient reactivation profile in J89GFP cells (Figure 1a), which is a lymphocyte HIV-1–latently infected cell line regarded as an experimentally tractable and relevant model to study post-integration HIV-1 latency and reactivation [74]. Moreover, the effects on primary CD4 T cell activation, measured as the surface expression iMFI (integrated median fluorescence intensity) of CD38 and CD69 activation markers, has been assessed (Figure 1b). Although minimal effects in comparison with the conventional phytohaemagglutinin (PHA) or PMA/ionomycin treatments were observed after panobinostat or romidepsin exposure, a combinatorial strategy could lead to a reduction in the concentrations of LRAs used in vivo, resulting in a reduction of adverse effects, limiting the local injuries, the toxicity, and the inflammation.

To date, several clinical trials involving HIV-1–infected adults are ongoing with the aim of evaluating the safety, tolerability and the potency of these potential antiviral latency agents [75–77]. However, no data regarding potential anti–latency drugs in HIV-1–infected paediatric patients are available. Therefore, owing to the established differences between paediatric and the adult HIV infection, we cannot be certain about the impact of these drugs in HIV paediatric patients and whether they will help to establish a functional cure in HIV-1–infected paediatric patients. The effect of panobinostat has been studied in children ranging from age 8 to 21 years with refractory haematological malignancies (https://clinicaltrials.gov/ct2/show/NCT01321346), and also in children older than 16 years with relapsing Hodgkin lymphoma (https://clinicaltrials.gov/ct2/show/NCT01169636). On the other hand, romidepsin has been used in patients younger than 21 years with recurrent solid tumours or leukaemias (https://clinicaltrials.gov/ct2/show/NCT00053963). These data suggest that it might be reasonable to design a clinical trial using these drugs in combination with cART in HIV-1 infected children and adolescents.

In summary, although there are still many obstacles before achieving a sterilising cure for HIV-1–infected paediatric patients, a functional cure could be close. Different approaches may be used to achieve it, although haematopoietic stem cell transplantation may not be used as a standard approach due to the elevated risks it carries. In recent infections, early cART may reduce the size of long-lived CD4+ T cell viral reservoirs that can be established, but the answers to several questions, such as the best cART and the optimum length of cART administration, remain elusive. Finally, in chronically HIV-infected paediatric patients, anti–latency drugs could have an important role but more information about the safety of these drugs in this population is required.

**Conflicts of interest and funding sources**

The authors declare that there are no conflicts of interest. This work has been (partially) funded by the RD12/0017/0037, project as part of the Plan Nacional R+D+i and co-financed by ISCIII– Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT13/0010/0028, Fondo de Investigacion Sanitaria (FIS) (PI13/02016), Comunidad de Madrid (grant number S-2010/BMD-2332), PENTA, CYTED 214RT0482. CIBER-BBN is an initiative funded by the VI National R+D+i Plan 2008–2011, IniciativaValencia 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Desarrollo Carlos III with assistance from the European Regional Development Fund. MMB is supported by ‘Red de Investigación en SIDA’ (RIS).

**References**

1. Faye A, Le Chenadec J, Dollfus C et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39: 1162–1168.
61. Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. *AIDS* 2013; 27: F7–F11.

62. Zhu J, Gaiha GD, John SP et al. Reactivation of latent HIV-1 by inhibition of BRD4. *Cell Rep* 2012; 2: 807–816.

63. Warilow D, Gardner J, Darnell GA et al. HIV type 1 inhibition by protein kinase C modulatory compounds. *AIDS Res Hum Retrovirus* 2006; 22: 854–864.

64. Kukskay J, Culnan DM, Roman J et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. *Blood* 2001; 98: 3006–3015.

65. Hamer DH, Bocklandt S, McHugh L et al. Rational design of drugs that induce human immunodeficiency virus replication. *J Virol* 2003; 77: 10227–10236.

66. Mehla R, Pawarkar-Mehla S, Zhang R et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. *PLoS One* 2010; 5: e11160.

67. del Real G, Jimenez-Baranda S, Mira E et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. *J Exp Med* 2004; 200: 541–547.

68. Perez M, de Vinuesa AG, Sanchez-Duffhues C et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. *Curr HIV Res* 2010; 8: 418–429.

69. Archin NM, Liberty AL, Kashuba AD et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature* 2012; 487: 482–485.

70. Rasmussen TA, Tolstrup M, Winckelmann A et al. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. *Hum Vaccin Immunother* 2013; 9: 790–799.

71. Yin H, Zhang Y, Zhou X, Zhu H. Histone deacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. *Mol Biol Rep* 2011; 38: 5071–5078.

72. Victoriano AF, Imai K, Tomori H et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. *FEBS Lett* 2011; 585: 1103–1111.

73. Furumai R, Matsuyama A, Kobashi N et al. PKZ28 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. *Cancer Res* 2002; 62: 4916–4921.

74. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. *J Virol* 2002; 76: 8776–8786.

75. Archin N M, Sung J M, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. *Nature Rev Microbiol* 2014; 12: 750–764.

76. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. *Retrovirology* 2013; 10: 67.

77. Katlama C, Deeks SG, Autran B et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. *Lancet* 2013; 381: 2109–2117.